Aktuellt
SENASTE
Redeye is encouraged to learn that Alzinova’s lead candidate, ALZ-101, met the primary endpoint of safety and tolerability in its phase Ib trial. Furthermore, patients treated with ALZ-101 demonstrated heightened antibody levels which increased with the number of doses given. We emphasize that the results are very positive for the company and argue that they warrant a strong positive share price reaction. We intend to raise our base case and will return with a more detailed review shortly.
LÄS MER
